Showing results (71-80 of 123) with videos related to
Sort By:
Pageof 13
Expert Opinion on Investigational Drugs|June 1, 2018
The role of 5 HT6-receptor antagonists in Alzheimer's disease: an updateRita Khoury, Noam Grysman, Jake Gold, et al.Dementia and Geriatric Cognitive Disorders|February 6, 2009
Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's diseaseGeorge T Grossberg, Vojislav Pejović, Michael L Miller, et al.Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|July 21, 2018
Empathy changes in neurocognitive disorders: A reviewZachary Bartochowski, Shravan Gatla, Rita Khoury, et al.International Journal of Geriatric Psychiatry|November 10, 2011
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapyMartin R Farlow, George T Grossberg, Xiangyi Meng, et al.American Journal of Alzheimer'S Disease and Other Dementias|December 7, 2010
Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's diseaseGeorge T Grossberg, Frederick A Schmitt, Xiangyi Meng, et al.The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 10, 2013
Prevalence of Parkinson disease and Parkinson disease dementia in community nursing homesMatthew Hoegh, Aalamgeer K Ibrahim, John Chibnall, et al.Current Psychiatry Reports|May 29, 2013
Caregiver health: health of caregivers of Alzheimer's and other dementia patientsTodd J Richardson, Soo J Lee, Marla Berg-Weger, et al.The Primary Care Companion for CNS Disorders|February 11, 2015
Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementiaCarl H Sadowsky, Joseph L Micca, George T Grossberg, et al.Expert Opinion on Pharmacotherapy|August 1, 2020
An update on the efficacy and safety of iloperidone as a schizophrenia therapyAjay Nair, Amanie Salem, Anna-Lee Asamoah, et al.Expert Opinion on Therapeutic Targets|July 21, 2023
The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's diseaseBret Silverglate, Xiaoyi Gao, Hannah P Lee, et al.Pageof 13